ANI CFO has 5,503 shares withheld for taxes

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition.

Accepted by SEC EDGAR 02/13/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On February 11, 2026, 5,503 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes in connection with the vesting of 16,210 performance stock units, a grant originally reported on April 6, 2023. After this non‑open‑market, tax‑withholding transaction, Carey directly beneficially owns 175,360 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 5,503 shares

Exercise Price or Tax Liability 1 txn

Insider CAREY STEPHEN P.

Role SVP & CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	5,503	$76.25	$420K

Holdings After Transaction: Common Stock — 175,360 shares (Direct)

Holdings Before and After: Common Stock, 180,863 to 175,360 shares (Direct)

Footnotes (1)

1. F1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 16,210 performance stock units, the grant of which was previously reported on April 6, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Stephen P. Carey?

ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey had 5,503 common shares withheld on February 11, 2026 to cover taxes. The withholding was tied to the vesting of 16,210 performance stock units previously granted on April 6, 2023.

Was the February 11, 2026 ANIP Form 4 transaction an open-market sale?

No, the February 11, 2026 transaction was a tax-withholding disposition, not an open-market sale. Shares were withheld under Rule 16(b)-3 to satisfy tax obligations arising from vesting of performance stock units granted in April 2023.

How many ANIP shares were withheld for taxes from Stephen P. Carey’s award?

A total of 5,503 ANI Pharmaceuticals common shares were withheld for tax purposes at $76.25 per share. This withholding related to the vesting of 16,210 performance stock units previously reported as granted on April 6, 2023.

How many ANI Pharmaceuticals (ANIP) shares does Stephen P. Carey own after the Form 4 transaction?

Following the February 11, 2026 tax-withholding transaction, Stephen P. Carey beneficially owns 175,360 shares of ANI Pharmaceuticals common stock. These shares are reported as directly held, reflecting his updated post-transaction ownership position.

What equity award triggered the tax-withholding on Stephen P. Carey’s ANIP shares?

The tax-withholding was triggered by the vesting of 16,210 performance stock units granted to Stephen P. Carey. This performance stock unit grant had been previously reported on April 6, 2023 and vested, creating a tax liability covered with withheld shares.

What does transaction code F indicate in the ANIP Form 4 for Stephen P. Carey?

Transaction code F indicates a tax-related disposition where shares are used to pay an exercise price or tax liability. In this case, 5,503 shares of ANI Pharmaceuticals common stock were withheld to satisfy taxes upon vesting of performance stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F		5,503(1)	D	$76.25	175,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 16,210 performance stock units, the grant of which was previously reported on April 6, 2023.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.